Article Text

Download PDFPDF

Effect of azithromycin on primary bronchial epithelial cells derived from stable lung allografts
  1. Desmond M Murphy1,
  2. Ian A Forrest1,
  3. Chris Ward1,
  4. Paul A Corris1,
  5. Gail E Johnson1,
  6. Debbie Jones1,
  7. Andrew J Fisher1,
  8. Jim J Egan2,
  9. Timothy E Cawston3,
  10. James L Lordan3
  1. 1Institute of Cellular Medicine, The University of Newcastle upon Tyne, Newcastle upon Tyne, UK
  2. 2The Irish Lung Transplant Programme, The Mater Hospital, Dublin, Ireland
  3. 3Institute of Cellular Medicine, The University of Newcastle upon Tyne, Newcastle upon Tyne, UK
  1. Correspondence to:
    Dr James L Lordan
    William Leech Centre for Lung Research, The Freeman Hospital, High Heaton, Newcastle upon Tyne NE7 7DN, UK;Jim.Lordan{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Obliterative bronchiolitis (OB), the main cause of lung allograft failure, is characterised by airway inflammation, neutrophilia, remodelling and fibrosis. Recent studies of the macrolide antibiotic azithromycin in OB, including one from our centre, have reported improved lung function with rescue therapy.1 The mechanism for this improvement remains unclear, but a recent study suggests that neutrophilic inflammation may be an important predictor of clinical response.2

Macrolides have anti-inflammatory properties in several pulmonary conditions. We hypothesised that the clinical benefit observed with azithromycin in patients undergoing lung transplantation may be related to the inhibition of factors key to airway neutrophilic inflammation, remodelling and fibrosis. The bronchial epithelium is in a pivotal position as a target and orchestrator of airway inflammation and remodelling. We tested our hypothesis using a unique primary bronchial epithelial cell (PBEC) model.3 The local research ethics committee approved the study.

Following pre-bronchoscopic assessment, surveillance bronchoscopy and bronchoalveolar lavage microbiology were performed to rule out infection. Bronchial brushings were obtained from subsegmental bronchi for PBEC cultures. Transbronchial specimens were examined to exclude acute vascular rejection. PBECs were established using endobronchial brushings from 10 clinically stable transplant recipients.

Azithromycin (Pfizer Ltd, Sandwich, UK) 20, 10 and 5 ng/ml was added to PBECs for 48 h before removal of cell supernatant and protein analysis with multiplex kits (R&D Systems Europe Ltd, Abingdon, UK) and a Luminex analyser. A methylene blue assay was used to correct data for PBEC cell number and the data were analysed using the Wilcoxon signed rank test.

Azithromycin caused a significant decrease in matrix metalloproteinase (MMP)-2, interleukin (IL)-8, granulocyte-macrophage colony stimulating factor (GM-CSF) and MMP-9 levels, with a trend towards decreased IL-6 production (table 1). Basal MMP-9 (2/10) and MMP-2 and GM-CSF levels (3/10) were below detection limits in some PBEC cultures. These factors are critical in orchestrating neutrophil influx, influencing antigen presenting cells and potentiating airway remodelling, which are relevant to the pathophysiology of OB. IL-8 is a neutrophil chemoattractant with additional roles in angiogenesis and remodelling, while IL-6 plays a part in B cell differentiation, monocyte proliferation, neutrophil recruitment, activation and degranulation, which may have pathophysiological roles in OB. GM-CSF regulates accumulation and activity of neutrophils and is increased in lung disease characterised by neutrophilic infiltration and in the post-transplant airway.4 It is also associated with an increased number and activity of antigen presenting cells, including activated dendritic cells.

Table 1

 Effect of azithromycin at concentrations of 5, 10 and 20 ng/ml on IL-8, GM-CSF, IL-6, MMP-2 and MMP-9 levels

It is assumed that fibroblasts are responsible for the production of scar collagen in chronic transplant rejection. We have shown potential for injured airway epithelial cells from allografts to become fibroblasts through epithelial mesenchymal transition (EMT) and have demonstrated a key role for MMPs in facilitating this phenotypic change.5 The ability of azithromycin to modulate the epithelial release of these factors is therefore consistent with a potential to influence alloimmunity, neutrophilic inflammation, EMT, remodelling and fibrosis. We therefore suggest that this may underlie the clinical benefit of azithromycin seen in certain patients, but further animal model and in vivo studies including random-ised trials are required.


View Abstract


  • Funded by the Newcastle upon Tyne Hospitals Special Trustees, ERS Fellowships (DMM and CW), MRC Fellowship (IAF), a GSK Fellowship (AJF), MRC project grant (CW and PAC) and the McPhail Trust (JLL).

  • Competing interests: None.